Home
About Us
Overview
Strategy
Technology and IP
R & D Pipeline
Management
Board
Scientific Advisors
History
Collaborations and Partners
Scientific Publications
Careers
Investors
Overview
Corporate Governance
Financial Reports
News Releases / Presentations
Shareholder Information
Share Price Information
Newsletters
Investor Contacts
Pharmaceuticals
Overview
Drug Delivery
TPM
Insulin
Oxycodone
Lidocaine
Diclofenac
Tretinoin
Nutraceuticals
Overview
Dietary Supplements
Functional Foods
Personal Care Products (inc. Elixia and Peau de Vierge)
Elixia Skincare Range
Investors
Overview
Corporate Governance
Financial Reports
News Releases / Presentations
Shareholder Information
Share Price Information
Newsletters
Investor Contacts
News Releases / Presentations
2010
TEST ITEM
2010 Sept 2 Phosphagenics Exercises Option to Licence AOD9604 to Develop Topical Cellulite Product
August 2010 Southern Cross Phosphagenics Report
2010 Aug 24 Phosphagenics Appoints Three New Non-Executive Directors to Boost its Commercial Transformation
2010 July 21 BioBusiness Asia 2010 presentation by Dr Ogru
2010 June 30 Pain Patch Technology Moves Forward
2010 June 8 BioMelbourne Network presentation by Dr Esra Ogru
2010 May 31 Adoption of New Constitution
2010 June 01 Appendix 3Z Final Director's Interest Notice
AGM 2010 Resolution Results
2010 May 31 AGM Chairman address and CEO presentation
May 2010 Southern Cross Phosphagenics Report
May 2010 Phosphagenics Company Presentation
2010 May 4 Notice of Annual General Meeting 31May and documentation
2010 Apr 29 Joint CEO Appointment - Dr E Ogru
2010 Apr 23 Annual Report 2009
2010 April 15 Chairman to Retire in May
2010 April 12 Phosphagenics Appoints Southern Cross as Corporate Advisor
2010 Mar 31 Phosphagenics Signs Global Agreement for Use of Transdermal Insulin in Companian Animals
Elixia Launch Sydney 23 March 2010 presentation by Dr Esra Ogru
2010 Mar 23 Phosphagenics and The Quigley Corporation Form JV to Develop and Market OTC Products
2010 Feb 03 Phosphagenics Launches Australian Skincare Products
2010 Feb 01 Positive Results Phase 1B Transdermal Oxycodone Patch
2010 Jan 13 Phosphagenics to present at OneMedForum 2010 and corporate presentation
2009
TEST ITEM
2009 Dec 17 Insulin Patch on Track for Clinical Trials
2009 Dec 15 Metabolic Syndrome Trial Results
2009 Dec 02 Oxycodone Phase 1B Patch Human Trial
2009 Nov 04 Major US Launch for Phosphagenics' Personal Care Products
2009 Oct 05 Share Purchase Plan
2009 Oct 05 Appendix 3Y M Ashton
2009 Oct 05 Appendix 3Y J Mills
2009 Oct 05 Appendix 3Y A Vizard
2009 Sep 15 Transdermal Oxycodone Matrix Patch Phase 1 Trial Successful Completion
2009 Sep 09 Phosphagenics to commence Phase 2/3 Topical Diclofenac Trial
2009 Investor presentation
2009 Aug 18 SPP - Variation to underwriting commitment
2009 August 13 Share Purchase Plan
2009 August 13 Metabolic Pharmaceuticals Agreement
2009 July 20 Phosphagenics to Launch Premium Cosmetics Products in USA in partnership with Metier Tribeca
2009 June 29 Phosphagenics Announces the Successful Completion of a Phase 1 Clinical Trial using TPM/Oxycodone
2009 June 19 Phosphagenics signs agreement with CSL to evaluate TPM technology
2009 May 29 Phosphagenics Announces Completion of Transdermal Patch Prototypes
2009 May 29 AGM Chairman address and COO presentation
2009 May 20 Phosphagenics Bio International Convention Presentation
2009 April 30 Retinoic Acid Trial Demonstates Increased Delivery and Reduced Irritation
2009 Apr 14 Annual Report 2008 and 2009 AGM documentation
2009 Feb 23 - Phosphagenics phase 1 topical Diclofenac study
2009 Feb 20 Appointment of Dr Esra Ogru as Chief Operating Officer and Dr Paul Gavin as Vice President, Research & Development
2009 Jan 28 Acquired Intangible Asset Valuation Review
2009 Jan 06 - Insulin trial on type 1 diabetic patients completed
2008
TEST ITEM
2008 Dec 08 - Positive clinical trial results for transdermal lidocaine
2008 Nov 12 - Transdermal diclofenac enters phase 1 clinical trial in humans
2008 Nov 05 - Metabolic syndrome phase 2 clinical trial recruitment completed
2008 Oct 07 Phosphagenics presentation at the annual pain therapeutics summit
2008 Sep 23 - Phosphagenics announces initiation of phase 1 clinical trial in humans for its transdermal lidocaine
2008 May 23 - AGM Results
2008 May 23 - AGM chairman's and ceo's addresses
2008 May 20 - Phosphagenics Executive Appointment
2008 May 07 - Phosphagenics completes a$9.1m capital raising
2008 Apr 30 - Phosphagenics reports positive pre-clinical results for targeted delivery of lidocaine
2008 Mar 19 - Phosphagenics initiates its phase 2 clinical trial in type 1 diabetes
2008 Mar 18 - GRAS status opens door to US food industry
2008 Feb 19 - Phosphagenics initiates clinical trial for its topical retinoic acid
2008 Feb 11 - Progression poh and nestle trial
2008 Jan 30 - Phosphagenics reports superior pre-clinical cholesterol results from apa-01 and atorvastatin combination
2008 Phosphagenics Annual Report
Older Releases
TEST ITEM
2007 Dec 17 - Successful transdermal oxycodone clinical trial results
2007 Dec 04 - Phosphagenics presentation bby 2007 healthcare life sciences conference
2007 Oct 04 - Nestle nutrition and Phosphagenics to commence phospha e phase 2 clinical_trial
2007 Sep 24 - Phase 1 transdermal oxycodone clinical trial approval
2007 Sep 17 - Phosphagenics to conduct a phase 1 oxycodone clinical trial
2007 Sep 12 - Phosphagenics to commence phase 2 tpm-insulin clinical trial
2007 Aug 08 - Positive phase 1b transdermal insulin clinical trial results
2007 June 21 - Phosphagenics dermal delivery breakthrough
2007 Jan 18 - Nestle Phospha E Option Agreement
2007 Jan 12- Nestle Nutrition enters commercial discussions with Phosphagenics
2006 Jan 18 - Morphine Phase 1b
2007 Mar 07 - Phosphagenics extends transdermal technology platform
2007 July 09 - Phosphagenics and Nestle extend option agreement
2007 Oct 19 - Dietary supplement update
2007 May 21 - AGM chairman's address
2007 - AGM chairman's address
2007 May 22 - Phase 1b insulin clinical trial commenced
2007 Jan 18 - Nestle excercises option to commercialise phospha e
2007 May 25 - AGM Results
2007 May 01 - Phosphagenics to commence insulin clinical trial
2007 - Annual Report and AGM documentation